

EFFICACY AND DURATION IN TREATMENT OF ACANTHAMOEBA KERATITIS. PREVALENCE AND RISK FACTOR OF THE INFECTION.



A. JOFRÉ¹, F. ÁVILA¹, M. AZNAR¹, J.E. MARTÍNEZ², A. MARTOS², D. GONZALEZ², J.A. MORALES², P.J. ACOSTA², J. URDA², M.A. CASTRO². ¹HOSPITAL DE PONIENTE, HOSPITAL PHARMACY, EL EJIDO, SPAIN. ²HOSPITAL DE PONIENTE, PHARMACY HOSPITAL, EL EJIDO, SPAIN.

BACKGROUND

Acanthamoeba keratitis (AK) is a serious corneal infection that may even lead to loss of eyes. Infection prevalence has increased in recent years as the use of contact lenses (CL).

PURPOSE

MATERIALS AND METHODS

Retrospective descriptive study in a second level hospital.

Total population of this study was 270000 inhabitants over a period of 3 years (2014-2016). The treatment was: (CED) with eye drops of 0.1% propamidine isethionate.

For data collection have been used the Farmatools[®] patient software and patient clinic history.

Data collected

Number of patients treated with (CED)

Demographic data

Microbiological results (cultures and PCR for Acanthamoeba spp)

Days of targeted treatment

Need for ocular surgery and use of (CL)

All (AK) together with Pseudomonas

spp. required surgical intervention.

Patients were treated with (CED): 36 (55.5%female). Average age: 35 years (18-90).	Microbiological Culture Results		In culture in which Acanthamoeba spp. was isolated, PCR was positive in 12 patients (75%).
	Acanthamoeba spp.	8 (22.2%)	
	Acanthamoeba spp. toguether Pseudomonas spp.	8 (22.2%)	
	Aspergillus spp.	4 (11%)	
	Pseudomonas spp. toguether Serratia spp.	4 (11%)	
	Pathogens were not isolated	12 (33%)	
The average duration of treatment with (CED) targeted to (AK) was	The prevalence of (AV) was 1 case par		e (AK) without <i>Pseudomonas</i> equired surgical intervention.

201 days (48-268).

RESULTS

CONCLUSIONS

Treatment with (CED) was effective in all patients with (AK) without Pseudomonas spp, but it was not effective in any patient with (AK) with Pseudomonas spp. The period of treatment with (CED) in (AK) was long, for the efficacy it was fundamental the adherence. This study shows a low prevalence according to criteria of the World Health Organization. The use of (CL) was a risk factor in the appearance of (AK).

The (AK) should be one of the first possibilities to consider when a user of (CL) suffers an atypical keratitis.

REFERENCES

Ophthalmology. pii: S0161-6420(16)32529-5. doi: 10.1016/j.ophtha.2017.05.012

(AK) was 1 case per

50,000 people / year.